FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Tinya Abrams

Research Profile

Chemicals & Drugs

Phenomena

Phosphorylation

Living Beings

Anatomy

Procedures

Concepts & Ideas

Time Factors

Physiology

Post Translational Protein Processing

Disorders

Bone Neoplasms

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Jason S Damiano; Millicent G Embry; Abdallah Fanidi; Majid Ghoddusi; Jocelyn Holash; Christopher Karim; Katherine G Rendahl; Tinya J Abrams; Judith A Abraham
Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Xiaohua Xin; Tinya J Abrams; Paul W Hollenbach; Katherine G Rendahl; Yan Tang; Yoko Oei; Millicent G Embry; Debbie E Swinarski; Evelyn N Garrett; Nancy K Pryer; Suzanne Trudel; Bahija Jallal; Dirk B Mendel; Carla Heise
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Pasquina Marzola; Anna Degrassi; Laura Calderan; Paolo Farace; Caterina Crescimanno; Elena Nicolato; Anna Giusti; Enrico Pesenti; Andrea Terron; Andrea Sbarbati; Tinya J Abrams; Lesley Murray; Francesco Osculati
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Tinya Abrams (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Jason S Damiano; Millicent G Embry; Abdallah Fanidi; Majid Ghoddusi; Jocelyn Holash; Christopher Karim; Katherine G Rendahl; Tinya J Abrams; Judith A Abraham
Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Molecular cancer therapeutics 2013;12(3):295-305.
2006: Xiaohua Xin; Tinya J Abrams; Paul W Hollenbach; Katherine G Rendahl; Yan Tang; Yoko Oei; Millicent G Embry; Debbie E Swinarski; Evelyn N Garrett; Nancy K Pryer; Suzanne Trudel; Bahija Jallal; Dirk B Mendel; Carla Heise
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4908-15.
2004: Pasquina Marzola; Anna Degrassi; Laura Calderan; Paolo Farace; Caterina Crescimanno; Elena Nicolato; Anna Giusti; Enrico Pesenti; Andrea Terron; Andrea Sbarbati; Tinya J Abrams; Lesley Murray; Francesco Osculati
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(2):739-50.
2003: Tinya J Abrams; Lesley J Murray; Enrico Pesenti; Vicky Walker Holway; Tina Colombo; Leslie B Lee; Julie M Cherrington; Nancy K Pryer
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Molecular cancer therapeutics 2003;2(10):1011-21.
2003: Tinya J Abrams; Leslie B Lee; Lesley J Murray; Nancy K Pryer; Julie M Cherrington
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Molecular cancer therapeutics 2003;2(5):471-8.
2003: Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood 2003;101(9):3597-605.
2003: Jastinder Sohal; Vernon T Phan; Philip V Chan; Elizabeth M Davis; Bhumi Patel; Louise M Kelly; Tinya J Abrams; Anne-Marie O'Farrell; D Gary Gilliland; Michelle M Le Beau; Scott C Kogan
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Blood 2003;101(8):3188-97.
2003: Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne-Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Clinical & experimental metastasis 2003;20(8):757-66.
2003: Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):327-37.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.